Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review

Background: Immune checkpoint blockade has revolutionized the treatment of multiple malignancies. Currently, however, the effect is not universal, with objective response rates (ORR) of about 15–25%, and even lower for some cancers. Abnormal vasculature is a hallmark of most solid tumors and plays a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Ling, Yang, Xi, Yi, Cheng, Zhu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6812341/
https://www.ncbi.nlm.nih.gov/pubmed/31680957
http://dx.doi.org/10.3389/fphar.2019.01173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6812341/
https://www.ncbi.nlm.nih.gov/pubmed/31680957
http://dx.doi.org/10.3389/fphar.2019.01173

Ejemplares similares